Market Place
Sourcing Support
Pfizer`s BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC
14 Sep 2024 //
BUSINESSWIRE
EMA validates Pierre Fabre`s MAA for BRAFTOVI
02 Nov 2023 //
PR NEWSWIRE
US clears Pfizer`s Braftovi, Mektovi combo for use in lung cancer
13 Oct 2023 //
BUSINESSWIRE
Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC
31 Aug 2023 //
ONCLIVE
Enforcement Report - Week of April 19, 2023
19 Apr 2023 //
FDA
FDA Confirms Paragraph IV Patent Litigation for Mektovi (Binimetinib)
24 Aug 2022 //
FDA
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
OnKure Begins Dosing in PIb/II Nautilus Trial of OKI-179 + Binimetinib
02 Jun 2022 //
GLOBENEWSWIRE
EORTC and Pierre Fabre launch phase 3 trial for melanoma
27 May 2022 //
PMLIVE
Pierre Fabre & EORTC open a large Phase III clinical study the adjuvant setting
24 May 2022 //
PRESS RELEASE
IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib
23 Mar 2021 //
PRNEWSWIRE
OnKure, Pfizer ink collaboration to evaluate Mektovi in combo with OKI-179
22 Sep 2020 //
PHARMABIZ
OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement
21 Sep 2020 //
BUSINESSWIRE
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196
09 Jul 2020 //
PRNEWSWIRE
IDEAYA Biosciences Doses 1ST Patient in Ph1 Comb Studyof IDE196 and Binimetinib
08 Jul 2020 //
PRNEWSWIRE
US FDA grants priority review status to Pfizer`s sNDA for Braftov
19 Dec 2019 //
PHARMABIZ
EMA validated Pierre Fabre’s application for a Braftov and Mektovi combination
08 Nov 2019 //
PHARMATIMES
Pierre Fabre to Present New Data at the ESMO Annual Congress
25 Sep 2019 //
BUSINESSWIRE
HSE reimburses Braftovi combo
23 Aug 2019 //
PHARMA TIMES
Pierre Fabre`s triplet therapy makes strong showing in colorectal cancer
09 Jul 2019 //
PHARMAFILE
Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer
08 Jul 2019 //
BIOSPACE
Pierre Fabre and its partner Array BioPharma announce interim analysis results
06 Jul 2019 //
BUSINESSWIRE
Array played with Pfizer’s eagerness to land a deal on time
01 Jul 2019 //
FIERCE PHARMA
BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor
18 Jun 2019 //
ENDPTS
Array BioPharma Announces Presentation of Updated from the Ph3 COLUMBUS
29 May 2019 //
PR NEWSWIRE
Array Biopharma`s Braftovi triple therapy meets both endpoints
22 May 2019 //
PHARMAFILE
Array BioPharma`s colorectal cancer combo treatment meets main goals
22 May 2019 //
REUTERS
BRAFTOVI+MEKTOVI Recommended by NCCN Guidelines for Colorectal Cancer
18 Mar 2019 //
PR NEWSWIRE
Pierre Fabre`s Mektovi (binimetinib) receives approval in Europe
12 Oct 2018 //
EMA
EU approves new option for metastatic melanoma
24 Sep 2018 //
PHARMA TIMES
Pierre Fabre Receives EU Approval for BRAFTOVI® + MEKTOVI®
22 Sep 2018 //
BUSINESSWIRE
Unraveling the mysteries of drug resistance in melanoma with CRISPR-Cas9
24 Aug 2018 //
FIERCE BIOTECH
Meeting highlights from the CHMP 23-26 July 2018
31 Jul 2018 //
EMA
NCCN Recommend BRAFTOVI+ MEKTOVI for BRAF-mutant Melanoma
14 Jul 2018 //
PR NEWSWIRE
Onco360 Selected for Encorafenib & Binimetinib Limited Distrbn Pharmacy Network
02 Jul 2018 //
BUSINESSWIRE
Array scores FDA nod for Braftovi, Mektovi melanoma combo
28 Jun 2018 //
FIERCE PHARMA
Pierre Fabre-Array BioPharma Announce Addl Results of Encorafenib & Binimetinib
04 Jun 2018 //
BUSINESSWIRE
Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Results
17 May 2018 //
BUSINESSWIRE
